Rhythm Pharmaceuticals, Inc. (RYTM) financial statements and ratios from SEC XBRL: revenue $0.3B (TTM), net margin -103.6%, revenue growth 45.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $189.76M |
| Revenue (TTM) | $0.3B |
| Net Margin | -103.6% |
| Operating Margin (TTM) | -77.1% |
| Net Debt / EBITDA | -0.2 |
| Revenue Growth (YoY) | 45.8% |
| EPS Growth (YoY) | -28.3% |
| FCF Growth (YoY) | 2.4% |
| Price / Book | 73.54 |
| Price / Sales | 31.19 |
| Altman Z-Score | 9.25 (safe) |
| Piotroski F-Score | 6/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
RYTM overview · RYTM earnings · RYTM KPIs · RYTM documents · RYTM ownership · RYTM peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.